Research progress on Th17 cell differentiation regulation mechanisms and therapeutic targets in ankylosing spondylitis
10.3969/j.issn.1006-5725.2025.18.024
- VernacularTitle:强直性脊柱炎中Th17细胞分化调控机制及其治疗靶点的研究进展
- Author:
Mingyang YU
1
;
Jia LI
1
;
Xinzhe FENG
1
;
Jingjing BI
1
;
Cheng LI
1
Author Information
1. 海军军医大学第一附属医院关节骨病外科(上海 200433)
- Publication Type:Journal Article
- Keywords:
ankylosing spondylitis;
Th17 cells;
IL-23/IL-17 axis;
signaling pathways;
targeted therapy;
transcriptional regulation;
bone remodeling
- From:
The Journal of Practical Medicine
2025;41(18):2953-2960
- CountryChina
- Language:Chinese
-
Abstract:
Ankylosing spondylitis(AS)is a chronic autoimmune disease characterized by inflammatory involvement of the axial skeleton and pathological bone formation.The T helper 17 cell(Th17 cell)subset of lym-phocytes plays a central role in mediating the inflammatory processes associated with AS.This review summarizes recent advances in the regulation of Th17 cell differentiation in AS,with a focus on the complex mechanisms governed by cytokine microenvironments,transcription factor networks,and metabolic and epigenetic regulatory pathways.Key regulatory components discussed include the IL-23/STAT3 signaling axis,the CCL20/CCR6 chemo-tactic axis,and the master transcription factor RORγt.Additionally,this review critically evaluates emerging thera-peutic strategies targeting metabolic reprogramming(e.g.,PKM2),epigenetic regulators(e.g.,JMJD3,EZH2),engineered exosome delivery systems,and modulators of metabolic enzymes.By analyzing the limitations of current treatment approaches,the review proposes future research directions emphasizing multi-target therapeutic strategies and highlights the importance of personalized medicine in achieving precise and effective treatment for AS.These developments reveal promising new avenues for modulating Th17-mediated immunity,offering transformative poten-tial for the clinical management of AS.
